WPAI

Lundbeck to Present Data on VYEPTI® (eptinezumab-jjmr) at the 64th Annual Scientific Meeting of the American Headache Society, Furthering Clinical and Real-World Evidence for Migraine Prevention

Retrieved on: 
Thursday, June 9, 2022
Health, Other Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Diamond, Woman, Eptinezumab, Neurological disorder, Caregiver, Headache, AHS, Research, Marketing, Lists of diseases, Nausea, Amitriptyline, Disease, Headache (journal), MHD, Steiner, Global Burden of Disease Study, Migraine, Failure, WPAI, CGRP, Disability, Patient, YLD, VAS, Calcitonin gene-related peptide, Topiramate, MSQ, Poster, LUN, Vomiting, Birth control, Pharmaceutical industry, Medical imaging, Aroma compound, Lundbeck, Virtual Private LAN Service

Lundbeck today announced data on VYEPTI (eptinezumab-jjmr) will be presented at the 64th Annual Scientific Meeting of the American Headache Society (AHS) taking place from June 9-12, 2022.

Key Points: 
  • Lundbeck today announced data on VYEPTI (eptinezumab-jjmr) will be presented at the 64th Annual Scientific Meeting of the American Headache Society (AHS) taking place from June 9-12, 2022.
  • A total of nine poster presentations will be shared to highlight clinical data and real-world analyses of eptinezumab as a preventive migraine treatment in adults.
  • These data continue to show the clinical benefit of VYEPTI as a preventive treatment option for people with migraine, said Marija Geertsen, M.D., Vice President, U.S. Medical Affairs, Lundbeck.
  • The safety of VYEPTI was evaluated in 2,076 patients with migraine who received at least one dose of VYEPTI.

Galapagos presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress

Retrieved on: 
Monday, October 4, 2021
Filgotinib, Medicines and Healthcare products Regulatory Agency, Review, Sandborn, TNF, PMDA, European Directive on Traditional Herbal Medicinal Products, Induction, Union, Health care, Methotrexate, Volume Ten, Safety, RA, EQ-5D, EMA, MHRA, Interview, European Medicines Agency, MTX, European, Adult, Work, Disease, Ulcerative colitis, Product, Inflammatory bowel disease, Tablet, Gilead, Inflammatory Bowel Diseases, Inflammation, Ministry of Health, Labour and Welfare, JAK1, Eisai, WPAI, IBQ, Gilead Sciences, Fibrosis, Mayo, MCS, Quality of life (healthcare), Week, Diagnosis, IBD, Galapagos NV, Patient, Disease-modifying antirheumatic drug, CHMP, European Union, Contraindication, Quality of life, Conditional sentence, Pharmaceutical industry, Medical device

In addition to the physical impact from flare ups, there is also a psychological impact associated with UC.

Key Points: 
  • In addition to the physical impact from flare ups, there is also a psychological impact associated with UC.
  • The European Summary of Product Characteristics for filgotinib, which includes contraindications and special warnings and precautions, is available at www.ema.europa.eu .
  • Filgotinib in UC has been filed in the European Union, Great-Britain and Japan, and a global Phase 3 program is ongoing in Crohns Disease.
  • Clinically meaningful improvements in health-related quality of life among patients with ulcerative colitis treated with filgotinib: post hoc analysis of the phase 2b/3 SELECTION study.